Robert W. Baird Forecasts Strong Price Appreciation for LivaNova (NASDAQ:LIVN) Stock

LivaNova (NASDAQ:LIVN - Free Report) had its price target increased by Robert W. Baird from $66.00 to $72.00 in a report issued on Thursday, Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other equities research analysts have also issued reports on the company. Needham & Company LLC increased their target price on LivaNova from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, July 31st. Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. The Goldman Sachs Group started coverage on LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 target price for the company. Finally, Stifel Nicolaus increased their target price on LivaNova from $70.00 to $72.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of "Buy" and an average target price of $69.17.

LivaNova Trading Up 0.5 %

NASDAQ:LIVN traded up $0.28 on Thursday, hitting $51.62. 522,997 shares of the stock were exchanged, compared to its average volume of 622,489. The stock has a market cap of $2.80 billion, a PE ratio of -86.03 and a beta of 1.00. The company has a current ratio of 3.45, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49. The stock has a fifty day moving average of $51.04 and a 200-day moving average of $53.14. LivaNova has a fifty-two week low of $42.75 and a fifty-two week high of $64.47.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.66 by $0.15. The company had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. As a group, equities analysts expect that LivaNova will post 2.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LivaNova

A number of hedge funds have recently bought and sold shares of LIVN. Point72 Asset Management L.P. grew its stake in LivaNova by 204.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company's stock valued at $70,479,000 after purchasing an additional 863,157 shares in the last quarter. First Light Asset Management LLC grew its stake in LivaNova by 591.1% during the 2nd quarter. First Light Asset Management LLC now owns 710,390 shares of the company's stock valued at $38,944,000 after purchasing an additional 607,598 shares in the last quarter. Great Lakes Advisors LLC acquired a new stake in LivaNova during the 2nd quarter valued at approximately $16,614,000. Mesirow Institutional Investment Management Inc. acquired a new stake in LivaNova during the 1st quarter valued at approximately $13,816,000. Finally, Driehaus Capital Management LLC grew its stake in LivaNova by 64.7% during the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company's stock valued at $29,824,000 after purchasing an additional 213,749 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.